1172 related articles for article (PubMed ID: 30473431)
1. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of [
Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
[No Abstract] [Full Text] [Related]
3. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
4. A Single-Arm, Low-Dose, Prospective Study of
Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
[TBL] [Abstract][Full Text] [Related]
5. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
8. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [
Ahmadzadehfar H; Wegen S; Yordanova A; Fimmers R; Kürpig S; Eppard E; Wei X; Schlenkhoff C; Hauser S; Essler M
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1448-1454. PubMed ID: 28488028
[TBL] [Abstract][Full Text] [Related]
9. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
10. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
11. Results of a Prospective Phase 2 Pilot Trial of
Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
[TBL] [Abstract][Full Text] [Related]
12. The value of tumor markers in men with metastatic prostate cancer undergoing [
Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
14. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
15. Extended therapy with [
Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
[TBL] [Abstract][Full Text] [Related]
16. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
[TBL] [Abstract][Full Text] [Related]
17. 225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry.
Rosar F; Burgard C; Rohloff LV; Blickle A; Bartholomä M; Maus S; Petto S; Schaefer-Schuler A; Ezziddin S
Clin Nucl Med; 2024 Jul; 49(7):621-629. PubMed ID: 38769643
[TBL] [Abstract][Full Text] [Related]
18. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
19.
Karimzadeh A; Heck M; Tauber R; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
J Nucl Med; 2023 Mar; 64(3):402-409. PubMed ID: 36137758
[TBL] [Abstract][Full Text] [Related]
20. [
Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
